Clinical Trial Update: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 1 study evaluating the safety and tolerability of CC-92328 in participants with relapsed or refrac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-92328

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED